Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets

TheFly reported connected January 22 that Roth Capital initiated sum of ARCT with a Buy standing and a $20 terms target. The steadfast noted that the company’s 2 mid-stage programs amusement objective enactment and person highest income imaginable that transcend $1 billion. Roth besides highlighted that ARCT shares are trading adjacent to their currency value, efficaciously pricing successful a 0% accidental of occurrence for these assets, which makes ARCT perchance 1 of the astir mispriced stocks successful uncommon disease.

Similarly, earlier connected January 6, Citigroup lowered its terms people for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) from $9 to $7 and maintained a Neutral rating. The steadfast highlighted opportunities successful SMID-cap biotech for 2026, peculiarly successful companies astatine the commercialized oregon near-commercial stage.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is simply a biotechnology institution processing mRNA‑based vaccines and RNA therapeutics utilizing proprietary transportation technologies. Its pipeline targets infectious diseases similar COVID‑19 and influenza, arsenic good arsenic uncommon liver and respiratory disorders.

While we admit the imaginable of ARCT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.